Tuesday, August 16, 2022 | Back issues
Courthouse News Service Courthouse News Service

Shareholder Class Action

Directors of Trubion Pharmaceuticals are selling the company too cheaply, through an unfair process, to Emergent BioSolutions, for the equivalent of $4.55 a share, or $97 million, shareholders say in Seattle Federal Court.

Read the Top 8

Sign up for the Top 8, a roundup of the day's top stories delivered directly to your inbox Monday through Friday.

Loading
Loading...